Takeda Pharmaceutical Company Limited Deferred Tax Expense Income
Takeda Pharmaceutical Company Limited (TAK) reported Deferred Tax Expense Income of -JPY 71.12 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxExpenseIncome · last filed 2025-06-25
| Period end | Deferred Tax Expense Income 12 month | Deferred Tax Expense Income 12 month as first filed |
|---|---|---|
| 2025-03-31 | -71.12B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | -198.75B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | -188.53B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | -136.11B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | -141.89B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | -343.90B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | -69.07B JPY 20-F · filed 2021-06-29 | -75.72B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | -7.26B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | -32.41B JPY 20-F · filed 2019-06-27 |